U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Petrie Farms - 09/22/2014
  1. Compliance Actions and Activities

WARNING LETTER

Petrie Farms Sep 22, 2014

Petrie Farms - 09/22/2014


Recipient:
Petrie Farms


United States

Issuing Office:
New York District Office

United States


  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 
New York District
158-15 Liberty Avenue
Jamaica, NY 11433         
(718) 340-7000 

 

September 22, 2014
 
WARNING LETTER NYK-2014-59
 
VIA UNITED POSTAL SERVICE
DELIVERY SIGNATURE REQUESTED
 
 
Daniel J. Petrie, Owner
Petrie Farms
5030 Sheehe Road
Arcade, New York 14009-9750
 
Dear Mr. Daniel J. Petrie;
 
On July 16 and July 29, 2014, the U.S. Food and Drug Administration (FDA) conducted an investigation of your dairy operation located at 5030 Sheehe Road, Arcade, New York. This letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) that we found during our investigation of your operation. You can find the FD&C Act and its associated regulations on the Internet through links on the FDA’s web page at www.fda.gov.
 
We found that you offered for sale an animal for slaughter as food that was adulterated. Under section 402(a)(2)(C)(ii) of the FD&C Act, 21 U.S.C. § 342(a)(2)(C)(ii), a food is deemed to be adulterated if it bears or contains a new animal drug that is unsafe under section 512 of the FD&C Act, 21 U.S.C. § 360b. Further, under section 402(a)(4) of the FD&C Act, 21 U.S.C. § 342(a)(4), a food is deemed to be adulterated if it has been held under insanitary conditions whereby it may have been rendered injurious to health.
 
Specifically, our investigation revealed that on or about December 2, 2013, you sold a bob veal calf, identified with ear tag (b)(4) and orange plastic tag (b)(4), for slaughter as food. On or about December 3, 2013, (b)(4), slaughtered this animal. United States Department of Agriculture, Food Safety and Inspection Service (USDA/FSIS) analysis of tissue samples collected from this animal identified the presence of 1.3 parts per million (ppm) of desfuroylceftiofur (marker residue for ceftiofur) in the kidney. FDA has established a tolerance of 0.4 ppm for residues of desfuroylceftiofur in the kidney tissue of cattle as codified in Title 21, Code of Federal Regulations (C.F.R.), Section 556.113(b)(3)(i) (21C.F.R. 556.113(b)(3)(i)).  The presence of this drug in edible tissue from this animal in this amount causes the food to be adulterated within the meaning of section 402(a)(2)(C)(ii) of the FD&C Act, 21 U.S.C. § 342(a)(2)(C)(ii).  
 
Our investigation also found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. For example, you failed to maintain complete treatment records. Food from animals held under such conditions is adulterated within the meaning of section 402(a)(4) of the FD&C Act, 21 U.S.C. § 342(a)(4).
 
We also found that you adulterated the new animal drug Excenel RTU EZ (ceftiofur hydrochloride, ANADA 144-288). Specifically, our investigation revealed that you did not use Excenel RTU EZ as directed by its approved labeling or veterinary prescription. Use of this drug in this manner is an extralabel use. See 21 C.F.R. 530.3(a). 
 
The extralabel use of approved animal or human drugs in animals is allowed under the FD&C Act only if the extralabel use complies with sections 512(a)(4) and (5) of the FD&C Act, 21 U.S.C. §§ 360b(a)(4) and (5), and 21 C.F.R. Part 530, including that the use must be by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian/client/patient relationship. 
 
Our investigation found that you administered Excenel RTU EZ to a bob veal calf with ear tag (b)(4) and orange plastic tag (b)(4) without following the indication for use as stated in the approved label. Your extralabel use of Excenel RTU EZ was not under the supervision of a licensed veterinarian, in violation of 21 C.F.R. 530.11(a), and your extralabel use of Excenel RTU EZ resulted in an illegal drug residue, in violation of 21 C.F.R. 530.11(d).  Certain uses of ceftiofur (e.g. unapproved for certain production classes) are prohibited for extralabel use in cattle by 21 C.F.R. 530.41(a)(13)(iii).   Because your use of this drug was not in conformance with the approved labeling and did not comply with 21 C.F.R. Part 530, you caused the drug to be unsafe under section 512(a) of the FD&C Act, 21 U.S.C. § 360b(a), and adulterated within the meaning of section 501(a)(5) of the FD&C Act, 21 U.S.C. § 351(a)(5).
 
The above is not intended to be an all-inclusive list of violations. As a producer of animals offered for use as food, you are responsible for ensuring that your overall operation and the food you distribute is in compliance with the law.
                      
You should take prompt action to correct the violations described in this letter and to establish procedures to ensure that these violations do not recur. Failure to do so may result in regulatory action without further notice such as seizure and/or injunction.
 
You should notify this office in writing of the steps you have taken to bring your firm into compliance with the law within fifteen (15) working days of receiving this letter. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the time frame within which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.
 
Please send your reply to the Food and Drug Administration, 158-15 Liberty Avenue, Jamaica, New York 11433, Attention: LCDR Frank Verni. If you have questions regarding any issues in this letter, please contact LCDR Frank Verni at 718-662-5702 or by email at Frank.Verni@fda.hhs.gov.
 
 
Sincerely yours,                                  
/S/  
Ronald Pace                                       
District Director                                 
New York District